In Part 2, Anna Seekatz, PhD and PhD candidate Sophie Millard highlight the need for precision microbial therapies tailored to host-specific gut environments.

Clemson University researchers Anna Seekatz, PhD, and PhD candidate Sophie Millard uncover how functional mismatches between donor microbes and recipient gut environments could limit the success of microbiome-based therapies.

A multicenter US study confirms that RBL is a safe and effective microbiota-based therapy with sustained remission in a high-risk, comorbid population.

Vaccine candidate demonstrates 26.6% higher relative efficacy in adults 50 and older, with strong protection across flu strains.

Findings from recent studies published in BMC Gastroenterology highlight practical diagnostic tools and novel therapeutic strategies to improve management of chronic hepatitis B.

Centers for Disease Control and Prevention report underscores need for improved surveillance, donor screening, and public awareness as rare WNV strain emerges and Powassan virus cases hit new high.

Several companies nationwide, with FDA oversight, recalled food products due to potential bacterial contamination, issuing consumer warnings to prevent foodborne illness.

Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

This week, the ACIP recommends clesrovimab for RSV protection in infants under 8 months without maternal immunity, ASM Microbe talk urges for creative funding solutions amid federal freezes to sustain research and careers, and more.

6–3 ruling preserves no-cost insurance coverage for preventive services such as HIV PrEP, contraceptives, and screenings.

Robert C Bransfield, MD, continues to share how vector-borne infections may trigger psychiatric symptoms not through direct brain infection, but by disrupting immune signaling and gene expression.

Screening for an immunological biomarker in the nasal passage can effectively rule out a respiratory virus — reducing the need for conventional PCR tests.

Johns Hopkins is offering its Pamela Tucker transplant and oncology infectious diseases course. Its director, Shmuel Shoham, MD, offers more information about this continuous education opportunity.

A retrospective study finds no significant difference in treatment failure between patients with obesity and those without.

John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.

Paul Feuerstadt, MD, FACG, AGAF, offers a glimpse of patients dealing with this and insights on improving patients’ quality of life, post-treatment with fecal microbiota, live-jslm (Rebyota [RBL]).

Dual ACIP votes endorse RSV antibody protection for infants and expand no-cost access through the Vaccines for Children program.

New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.

The philanthropic organization plans to provide the gift over the next 5 years, and is in contrast with what is happening with US vaccine funding to the organization as well as the country's changing immunization policies.

Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.

More than 80% of patients had drug-related problems, highlighting the need for inpatient antiretroviral stewardship.

Rodney Rohde, PhD, SM(ASCP), SVCM, MBCM, FACSc, discusses the ongoing concerns about the federal government’s hold on funding for research and the potential chilling effect that it may have on laboratory professionals and deciding on careers, especially in areas such as public health. He also talks about locating and engaging in potential alternative resources for research funding.

New longitudinal study findings suggest booster vaccination may not be necessary despite declining antibody levels.

Application of GBD methods reveals substantial RSV-attributable hospitalizations and informs vaccine and surveillance strategies.